On the basis of these premises, we decided to conduct a study exploring the impact of different biomarkers, including KRAS, MET and IGF1R, on primary resistance to cetuximab therapy in metastatic, chemorefractory, and CRC with known EGFR FISH status. Here, IGF1R is linked to colorectal carcinoma.